Document is current
Any future updates will be listed below
-
Authors
Verschoor, Arie Jan https://orcid.org/0000-0001-9972-4241
Litière, Saskia https://orcid.org/0000-0002-6433-4056
Marréaud, Sandrine https://orcid.org/0000-0002-3205-3858
Judson, Ian https://orcid.org/0000-0002-4766-5304
Toulmonde, Maud https://orcid.org/0000-0003-3896-9274
Wardelmann, Eva https://orcid.org/0000-0001-6788-4910
LeCesne, Axel
Gelderblom, Hans https://orcid.org/0000-0001-9270-8636
-
Funding
Funding for this research was provided by:
European Organisation for Research and Treatment of Cancer
- License Information
-
More Information
Article History
Received: 20 January 2020
Accepted: 14 August 2020
First Online: 9 September 2020
Ethics approval and consent to participate
: All patients consented to participate in the different trials. For all studies, ethical approval was provided by the medical ethical committees of the different participating hospitals. Information about the ethics approval is provided in the manuscripts of the individual studies.
: Not applicable.
: AJV, SL, SM, IJ, MT and HG have nothing to disclose. ALC reports personal fees from Pharmamar, Lilly, Novartis and Amgen, all outside the submitted work. EW reports personal fees from Novartis, Lilly, Nanobiotix, Bayer, PharmaMar, Milestone, Menarini and New Oncology, all outside the submitted work.
